



June 28, 2021

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

“Strides announces successful completion of EU GMP inspection at Puducherry facility”

Thanks & Regards,

For **Strides Pharma Science Limited**,

A handwritten signature in blue ink that reads 'Manjula R.'.

Manjula Ramamurthy
Company Secretary



Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

Strides announces successful completion of EU GMP inspection at Puducherry facility

Continued GMP compliance status for the facility

Bengaluru, June 28, 2021 – Strides Pharma Science Limited (Strides) today announced the successful completion of the EU GMP inspection carried out by the National Institute of Pharmacy and Nutrition (OGYÉI), Hungary at its Puducherry facility on April 28, 2021. The Company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection. The company in August 2020 had also announced successful completion of the UK MHRA inspection at the site. The Puducherry facility caters to the U.S., Other Regulated Markets and Institutional businesses and has capabilities to produce finished dosage formulation products across multiple dosage formats.

Commenting on the development, **Dr. R. Ananthanarayanan, Managing Director & CEO**, remarked *“We are pleased with the positive outcome of the recent EU GMP inspection at our Puducherry facility. The positive result of this inspection underscores our commitment to regulatory excellence at our global manufacturing sites. We stay focused on getting the facility reclassified with the USFDA”*

About Strides

Strides, listed on the BSE (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

Strides**Badree Komandur**

Executive Director & Group CFO
+91 80 6784 0747

Investor Relations:

Sandeep Baid: +91 80 6784 0791
Email: Sandeep.baid@strides.com

PR Consultancy

Fortuna PR

K Srinivas Reddy: +91 90005 27213
srinivas@fortunapr.com

K Priya: +91 95354 25418
priya@fortunapr.com

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17,
Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta
Road, Bengaluru – 560 076